Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight, potentially making half the population candidates for its weight-loss drugs Ozempic and Wegovy.
The federal government is reluctant to reimburse the so-called GLP-1 drugs for weight loss, but Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can be up to $460 a month.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。